UA69924U - Способ диагностики аллергодерматозов - Google Patents
Способ диагностики аллергодерматозов Download PDFInfo
- Publication number
- UA69924U UA69924U UAU201106092U UAU201106092U UA69924U UA 69924 U UA69924 U UA 69924U UA U201106092 U UAU201106092 U UA U201106092U UA U201106092 U UAU201106092 U UA U201106092U UA 69924 U UA69924 U UA 69924U
- Authority
- UA
- Ukraine
- Prior art keywords
- diagnosis
- allergic
- clinical
- dermatoses
- etiological
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 38
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 29
- 230000000172 allergic effect Effects 0.000 title claims abstract description 27
- 208000017520 skin disease Diseases 0.000 title claims abstract description 11
- 239000013566 allergen Substances 0.000 claims abstract description 23
- 210000004369 blood Anatomy 0.000 claims abstract description 17
- 239000008280 blood Substances 0.000 claims abstract description 17
- 238000003748 differential diagnosis Methods 0.000 claims abstract description 14
- 230000001900 immune effect Effects 0.000 claims abstract description 13
- 206010048768 Dermatosis Diseases 0.000 claims abstract description 7
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 6
- 231100000331 toxic Toxicity 0.000 claims abstract description 6
- 230000002588 toxic effect Effects 0.000 claims abstract description 6
- 238000003759 clinical diagnosis Methods 0.000 claims abstract description 5
- 238000012360 testing method Methods 0.000 claims description 29
- 208000026935 allergic disease Diseases 0.000 claims description 11
- 206010020751 Hypersensitivity Diseases 0.000 claims description 10
- 230000000877 morphologic effect Effects 0.000 claims description 7
- 238000011161 development Methods 0.000 claims description 6
- 238000012549 training Methods 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 5
- 238000012790 confirmation Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 2
- 239000011780 sodium chloride Substances 0.000 abstract description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000013068 control sample Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- 208000024780 Urticaria Diseases 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 206010013700 Drug hypersensitivity Diseases 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 201000005311 drug allergy Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 3
- 229930003451 Vitamin B1 Natural products 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- 235000010374 vitamin B1 Nutrition 0.000 description 3
- 239000011691 vitamin B1 Substances 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000005460 biophysical method Methods 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000028571 Occupational disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- 206010042254 Strongyloidiasis Diseases 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000640 hair analysis Toxicity 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007459 negative regulation of leukocyte migration Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Способ диагностики аллергодерматозов включает сбор аллергологического анамнеза и проведение клинических, иммунологических и аллергологических исследований. Собирают аллергологический анамнез и описывают дерматологический статус. Далее проводят дифференциальную диагностику с другими дерматозами и инфекционными заболеваниями. После этого устанавливают клинический диагноз. При этом контрольные и опытные образцы цитратной крови инкубируют соответственно с физиологическим раствором и аллергенами. Далее проводят дифференциальную диагностику аллергодерматозов с псевдоаллергическим и токсическими реакциями и устанавливают клинико-этиологический диагноз.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201106092U UA69924U (ru) | 2011-05-16 | 2011-05-16 | Способ диагностики аллергодерматозов |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201106092U UA69924U (ru) | 2011-05-16 | 2011-05-16 | Способ диагностики аллергодерматозов |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA69924U true UA69924U (ru) | 2012-05-25 |
Family
ID=52280853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU201106092U UA69924U (ru) | 2011-05-16 | 2011-05-16 | Способ диагностики аллергодерматозов |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA69924U (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2659029C1 (ru) * | 2017-06-27 | 2018-06-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) | Способ диагностики лихеноидной реакции кожи |
-
2011
- 2011-05-16 UA UAU201106092U patent/UA69924U/ru unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2659029C1 (ru) * | 2017-06-27 | 2018-06-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) | Способ диагностики лихеноидной реакции кожи |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stothard et al. | An evaluation of urine-CCA strip test and fingerprick blood SEA-ELISA for detection of urinary schistosomiasis in schoolchildren in Zanzibar | |
| Carter et al. | Laboratory testing improves diagnosis and treatment outcomes in primary health care facilities | |
| Juthani-Mehta et al. | Role of dipstick testing in the evaluation of urinary tract infection in nursing home residents | |
| Kaminsky et al. | Unsuspected Strongyloides stercoralis infection in hospital patients with comorbidity in need of proper management | |
| Lahita et al. | Lupus Q&A: Everything You Need to Know | |
| Sisu et al. | Intestinal parasite infections in diabetes mellitus patients; A cross-sectional study of the Bolgatanga municipality, Ghana | |
| Chan et al. | Initial collection of an inadequate 24-hour urine sample in children does not predict subsequent inadequate collections | |
| Bogavac-Stanojević et al. | Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis | |
| UA69924U (ru) | Способ диагностики аллергодерматозов | |
| Shajari et al. | Screening of renal diseases in the first primary school children in Shiraz | |
| Lawee | Uric acid: the clinical application of 1000 unsolicited determinations. | |
| Ramos-Rincón et al. | Medical diagnosis in resource-poor tropical countries | |
| RU2367952C1 (ru) | Способ экспресс-диагностики туберкулезной инфекции | |
| RU2399055C2 (ru) | Способ диагностики туберкулезной инфекции | |
| Aid et al. | Standard operating procedures | |
| Azeez et al. | Socio-Demographic Profile, Asymptomatic Malaria Parasitaemia and Glycemic Control among Midled-Aged and Elderly Type 2 Diabetes Mellitus Patients in Rural Southwestern Nigeria: A Cross Sectional Study | |
| RU2027193C1 (ru) | Способ диагностики аллергии | |
| Hood et al. | Patient Activation and Quality of Life in Patients with Rare Kidney Disease. | |
| Tabassum et al. | Analysis of urine as an indicator of specific body conditions in pregnant women in rural mountainous region | |
| Yameny | The validity of the Questionnaire to identify Schistosoma haematobium infection | |
| Ekwebene et al. | Asymptomatic Bacteuria among Healthy Cohort Using Dipstick Urinalysis from a Tertiary Health Care Facility in South East Nigeria | |
| Cooppan et al. | Urinalysis reagent strips in the screening of children for urinary schistosomiasis in the RSA | |
| Al-Omary et al. | Lymphocyte Apoptosis in Third Trimester of Pregnancy. | |
| Cannon et al. | P113 Acceptability and Preferences for Using a Novel Device to Self-Collect Blood Specimens for HIV Pre-Exposure Prophylaxis (PrEP) Laboratory Monitoring | |
| RU2323441C2 (ru) | Способ диагностики сенсибилизации к водорастворимым промышленным аллергенам |